1. Home
  2. PCYO vs ACIU Comparison

PCYO vs ACIU Comparison

Compare PCYO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pure Cycle Corporation

PCYO

Pure Cycle Corporation

N/A

Current Price

$10.93

Market Cap

249.5M

Sector

Utilities

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.61

Market Cap

247.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCYO
ACIU
Founded
1976
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
249.5M
247.6M
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
PCYO
ACIU
Price
$10.93
$2.61
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $10.00
AVG Volume (30 Days)
78.1K
★ 149.7K
Earning Date
04-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 12.50
N/A
EPS
★ 0.36
N/A
Revenue
★ $1,227,787.00
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
$30.19
★ N/A
Revenue Growth
★ 171.54
N/A
52 Week Low
$9.71
$2.10
52 Week High
$12.44
$4.00

Technical Indicators

Market Signals
Indicator
PCYO
ACIU
Relative Strength Index (RSI) 41.39 42.92
Support Level $10.46 $2.13
Resistance Level $11.03 $2.68
Average True Range (ATR) 0.17 0.13
MACD -0.04 -0.03
Stochastic Oscillator 37.10 24.89

Price Performance

Historical Comparison
PCYO
ACIU

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: